Aerovate Therapeutics Quarterly Cash Flow Statements Chart
Quarterly
|
Annual
Aerovate Therapeutics Quarterly Cash Flow Statements Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| cash flows from operating activities: | ||||||||||||||||
| net income | -67,785,000 | -2,518,000 | -5,430,000 | -16,237,000 | -24,775,000 | -23,186,000 | -20,413,000 | -19,563,000 | -19,025,000 | -16,520,000 | -15,022,000 | -13,588,000 | -11,991,000 | -10,910,000 | -8,223,000 | -6,184,000 |
| adjustments to reconcile net income to net cash from operating activities: | ||||||||||||||||
| change in fair value of convertible notes payable | ||||||||||||||||
| stock-based compensation | ||||||||||||||||
| non-cash lease expense | ||||||||||||||||
| depreciation expense | 3,000 | |||||||||||||||
| changes in operating assets and liabilities: | ||||||||||||||||
| prepaid expenses and other current assets | -1,689,000 | 331,000 | 381,000 | 4,683,000 | -2,653,000 | -2,112,000 | 611,000 | -30,000 | -734,000 | 636,000 | 302,000 | -1,118,000 | 3,364,000 | 2,129,000 | -4,734,000 | -2,065,000 |
| other assets | ||||||||||||||||
| accounts payable | 5,093,000 | -155,000 | -684,000 | -3,271,000 | 948,000 | 835,000 | -1,044,000 | -2,014,000 | 773,000 | 2,121,000 | -1,749,000 | 2,242,000 | -712,000 | 1,587,000 | -1,045,000 | 1,091,000 |
| accrued expenses and other current liabilities | ||||||||||||||||
| related party accrued expenses and other current liabilities | ||||||||||||||||
| net cash from operating activities | -36,535,000 | -2,381,000 | -11,047,000 | -16,043,000 | -20,433,000 | -23,673,000 | -14,800,000 | -15,611,000 | -14,943,000 | -11,424,000 | -14,865,000 | -9,720,000 | -8,876,000 | -5,661,000 | -13,093,000 | -6,526,000 |
| capex | 0 | 0 | 0 | 0 | 0 | 0 | -64,000 | -32,000 | -30,000 | 14,000 | -4,000 | -33,000 | -130,000 | 57,000 | -98,000 | -56,000 |
| free cash flows | -36,535,000 | -2,381,000 | -11,047,000 | -16,043,000 | -20,433,000 | -23,673,000 | -14,864,000 | -15,643,000 | -14,973,000 | -11,410,000 | -14,869,000 | -9,753,000 | -9,006,000 | -5,604,000 | -13,191,000 | -6,582,000 |
| cash flows from investing activities: | ||||||||||||||||
| purchases of property and equipment | -64,000 | -32,000 | -30,000 | -16,000 | -4,000 | -33,000 | -130,000 | -28,000 | -85,000 | -56,000 | ||||||
| net cash from investing activities | -12,986,000 | 12,850,000 | 13,129,000 | 16,067,000 | 18,000,000 | 8,833,000 | 5,648,000 | -13,130,000 | 3,983,000 | 15,375,000 | 14,486,000 | 4,645,000 | 8,194,000 | -20,399,000 | -113,338,000 | -56,000 |
| cash flows from financing activities: | ||||||||||||||||
| proceeds from the pre-closing financing, net of 14,548 of offering costs | ||||||||||||||||
| cash acquired in connection with the reverse recapitalization | ||||||||||||||||
| net cash from financing activities | 554,000 | 22,000 | 24,380,000 | 471,000 | 463,000 | 20,000 | 45,290,000 | 223,000 | 357,000 | 37,000 | -250,000 | 128,310,000 | ||||
| net increase in cash and cash equivalents | 141,087,000 | 10,469,000 | 2,636,000 | 46,000 | 21,947,000 | -14,369,000 | -8,689,000 | -28,721,000 | 34,330,000 | 4,174,000 | -22,000 | -26,060,000 | ||||
| cash and cash equivalents at beginning of period | ||||||||||||||||
| cash and cash equivalents at end of period | ||||||||||||||||
| supplemental disclosure of non-cash operating, investing, and financing activities: | ||||||||||||||||
| purchases of property and equipment in accounts payable | 30,000 | 85,000 | -13,000 | |||||||||||||
| deferred offering costs reclassified from other assets to equity | ||||||||||||||||
| deferred offering costs in accounts payable | ||||||||||||||||
| operating lease liability arising from obtaining right-of-use asset | ||||||||||||||||
| prepaids and other current assets acquired in connection with the reverse recapitalization | ||||||||||||||||
| other liabilities assumed in connection with the reverse recapitalization | ||||||||||||||||
| convertible note principal and non-cash accrued interest converted to common stock and pre-funded warrants | ||||||||||||||||
| non-cash exchange of series seed convertible preferred stock for company series a non-voting convertible preferred stock | ||||||||||||||||
| cash flow from operating activities: | ||||||||||||||||
| stock-based compensation expense | 1,185,000 | 1,243,000 | 2,003,000 | 3,865,000 | 4,200,000 | 3,251,000 | 3,237,000 | 3,034,000 | 2,384,000 | 1,729,000 | 1,499,000 | 1,224,000 | 1,024,000 | |||
| depreciation and amortization expense | 4,000 | 8,000 | 218,000 | 28,000 | 28,000 | 28,000 | 25,000 | 22,000 | 21,000 | 20,000 | 20,000 | 17,000 | 11,000 | |||
| accretion of discounts and amortization of premiums on investments | -225,000 | -336,000 | -461,000 | -692,000 | -759,000 | -939,000 | -808,000 | -639,000 | -671,000 | -586,000 | -292,000 | -61,000 | 29,000 | |||
| other long-term assets | -226,000 | -1,721,000 | 2,508,000 | 2,000 | -40,000 | -15,000 | 34,000 | -89,000 | -1,465,000 | 21,000 | -403,000 | -25,000 | -24,000 | -204,000 | ||
| accrued and other liabilities | -1,151,000 | -5,761,000 | -1,697,000 | 606,000 | -3,061,000 | 4,051,000 | 3,394,000 | 1,838,000 | 716,000 | 2,037,000 | 1,444,000 | -306,000 | 497,000 | |||
| operating lease assets and liabilities | -54,000 | -329,000 | 221,000 | 11,000 | -12,000 | -35,000 | 52,000 | -12,000 | -31,000 | 2,000 | 52,000 | |||||
| other liabilities | 202,000 | -169,000 | 219,000 | -279,000 | 392,000 | -270,000 | 111,000 | -234,000 | 9,000 | |||||||
| | ||||||||||||||||
| cash flow from investing activities: | ||||||||||||||||
| purchases of short-term investments | 0 | -4,933,000 | 0 | -14,750,000 | -27,788,000 | -47,848,000 | -32,737,000 | -15,609,000 | -50,260,000 | -25,572,000 | -38,901,000 | -32,890,000 | ||||
| maturities of short-term investments | 12,850,000 | 13,129,000 | 21,000,000 | 18,000,000 | 23,583,000 | 33,500,000 | 34,750,000 | 36,750,000 | 31,000,000 | |||||||
| cash flow from financing activities: | ||||||||||||||||
| payments for offering costs | 0 | 0 | -74,000 | -233,000 | 0 | -75,000 | ||||||||||
| proceeds from issuance of common stock upon exercise of stock options | 247,000 | 22,000 | 511,000 | 704,000 | 335,000 | 95,000 | ||||||||||
| cash and cash equivalents at the beginning of the year | 33,751,000 | 0 | 0 | 0 | 23,491,000 | 0 | 0 | 0 | 22,397,000 | 0 | 0 | 0 | 54,197,000 | 0 | 0 | |
| cash and cash equivalents at the end of the period | 44,220,000 | 2,636,000 | 46,000 | 21,947,000 | 9,122,000 | -8,689,000 | -28,721,000 | 34,330,000 | 26,571,000 | -22,000 | -5,038,000 | -680,000 | 28,137,000 | -126,681,000 | 121,728,000 | |
| supplemental disclosure of noncash investing and financing activities: | ||||||||||||||||
| right-of-use asset obtained in exchange for operating lease liability | 0 | 0 | 0 | 206,000 | 0 | 0 | -41,000 | |||||||||
| deferred offering costs included in accounts payable | 82,000 | 104,000 | -134,000 | 148,000 | -1,651,000 | |||||||||||
| impairment of right-of-use asset | ||||||||||||||||
| proceeds from sale of common stock in connection with atm | 307,000 | 0 | 0 | 0 | ||||||||||||
| proceeds from issuance of common stock under espp | 0 | 0 | 128,000 | 0 | ||||||||||||
| purchases of property and equipment in accounts payable and accrued liabilities | ||||||||||||||||
| offering costs included in accounts payable | ||||||||||||||||
| proceeds from exercise of stock options | 223,000 | 443,000 | ||||||||||||||
| sales and maturities of short-term investments | 64,750,000 | 30,250,000 | 47,225,000 | 12,519,000 | ||||||||||||
| proceeds from sale of series a redeemable convertible preferred stock, net of issuance costs | 0 | 0 | ||||||||||||||
| payments for deferred offering costs | -236,000 | |||||||||||||||
| proceeds from issuance of common stock, net of issuance costs | -250,000 | |||||||||||||||
| conversion of redeemable convertible preferred stock to common stock upon initial public offering | ||||||||||||||||
| net increase in cash | -126,681,000 | 121,728,000 | ||||||||||||||
| operating lease asset and liability | -3,000 | 16,000 | ||||||||||||||
| non-cash interest expense | ||||||||||||||||
| change in fair value of convertible promissory notes to related party | ||||||||||||||||
| purchases of investments | ||||||||||||||||
| proceeds from issuance of convertible promissory notes to related party | ||||||||||||||||
| conversion of convertible promissory notes to related party to series a redeemable convertible preferred stock | ||||||||||||||||
| stock based compensation expense | 845,000 | |||||||||||||||
| accrued and other current liabilities | -28,000 |
We provide you with 20 years of cash flow statements for Aerovate Therapeutics stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as operating cash flows, cash levels, capital expenditures, profits, stock-based compensations and profit margins. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Aerovate Therapeutics stock. Explore the full financial landscape of Aerovate Therapeutics stock with our expertly curated income statements.
The information provided in this report about Aerovate Therapeutics stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.